188 related articles for article (PubMed ID: 31294338)
1. Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.
Chowdary P; Carcao M; Holme PA; Jiménez-Yuste V; Lentz SR; Møss J; Poulsen LH; Shen C; Tosetto A; Wheeler A; Santagostino E
Res Pract Thromb Haemost; 2019 Jul; 3(3):542-554. PubMed ID: 31294338
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
[TBL] [Abstract][Full Text] [Related]
4. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A.
Tiede A; Hampton K; Jiménez-Yuste V; Young G; Benchikh El Fegoun S; Chowdary P
Haemophilia; 2022 Jan; 28(1):27-35. PubMed ID: 34562332
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
[TBL] [Abstract][Full Text] [Related]
8. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
Tiede A; Brand B; Fischer R; Kavakli K; Lentz SR; Matsushita T; Rea C; Knobe K; Viuff D
J Thromb Haemost; 2013 Apr; 11(4):670-8. PubMed ID: 23398640
[TBL] [Abstract][Full Text] [Related]
10. Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response.
Chowdary P; Hampton K; Jiménez-Yuste V; Young G; Benchikh El Fegoun S; Cooper A; Scalfaro E; Tiede A
Thromb Haemost; 2022 Jun; 122(6):913-925. PubMed ID: 34865209
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.
Giangrande P; Abdul Karim F; Nemes L; You CW; Landorph A; Geybels MS; Curry N
J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):5-14. PubMed ID: 32544297
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
13. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results.
Kenet G; Young G; Chuansumrit A; Matsushita T; Yadav V; Zak M; Male C
J Thromb Haemost; 2023 Nov; 21(11):3109-3116. PubMed ID: 37597724
[TBL] [Abstract][Full Text] [Related]
14. Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP).
Klamroth R; Hampton K; Saulyte Trakymienė S; Korsholm L; Carcao M
Patient Prefer Adherence; 2021; 15():2443-2454. PubMed ID: 34764641
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
[TBL] [Abstract][Full Text] [Related]
16. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
[TBL] [Abstract][Full Text] [Related]
17. Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.
Lentz SR; Kavakli K; Klamroth R; Misgav M; Nagao A; Tosetto A; Jørgensen PJ; Zak M; Nemes L
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12674. PubMed ID: 35308099
[TBL] [Abstract][Full Text] [Related]
18. Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A.
Vashi P; Batt K; Klamroth R; Mancuso ME; Majewska R; Tiede A; Mantovani LG
J Blood Med; 2021; 12():935-943. PubMed ID: 34754257
[TBL] [Abstract][Full Text] [Related]
19. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
